Ultragenyx Pharmaceutical Inc (RARE)
42.60
+1.48
(+3.60%)
USD |
NASDAQ |
May 16, 16:00
42.60
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Cash from Financing (Quarterly): -0.058M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -0.058M |
December 31, 2023 | 330.61M |
September 30, 2023 | 25.23M |
June 30, 2023 | 33.02M |
March 31, 2023 | -0.722M |
December 31, 2022 | 1.882M |
September 30, 2022 | 491.88M |
June 30, 2022 | 5.837M |
March 31, 2022 | 1.612M |
December 31, 2021 | 85.72M |
September 30, 2021 | 7.55M |
June 30, 2021 | 12.63M |
March 31, 2021 | 12.65M |
December 31, 2020 | 489.71M |
September 30, 2020 | 19.14M |
June 30, 2020 | 35.81M |
March 31, 2020 | 55.62M |
December 31, 2019 | 315.44M |
September 30, 2019 | 0.904M |
June 30, 2019 | 9.342M |
March 31, 2019 | 353.62M |
December 31, 2018 | 12.24M |
September 30, 2018 | 25.02M |
Date | Value |
---|---|
June 30, 2018 | 13.17M |
March 31, 2018 | 286.42M |
December 31, 2017 | 64.44M |
September 30, 2017 | 1.333M |
June 30, 2017 | 1.526M |
March 31, 2017 | 68.97M |
December 31, 2016 | 74.94M |
September 30, 2016 | 63.45M |
June 30, 2016 | -0.025M |
March 31, 2016 | 0.314M |
December 31, 2015 | 0.887M |
September 30, 2015 | 288.65M |
June 30, 2015 | 2.595M |
March 31, 2015 | 175.44M |
December 31, 2014 | 0.412M |
September 30, 2014 | 60.51M |
June 30, 2014 | 0.01M |
March 31, 2014 | 124.04M |
December 31, 2013 | 0.038M |
September 30, 2013 | 0.076M |
June 30, 2013 | 0.056M |
March 31, 2013 | 0.001M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.722M
Minimum
Mar 2023
491.88M
Maximum
Sep 2022
96.69M
Average
15.89M
Median
Cash from Financing (Quarterly) Benchmarks
Corcept Therapeutics Inc | -0.543M |
Madrigal Pharmaceuticals Inc | 573.71M |
Sarepta Therapeutics Inc | 22.14M |
FibroGen Inc | -0.165M |
Rocket Pharmaceuticals Inc | 1.184M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -190.73M |
Cash from Investing (Quarterly) | 94.44M |
Free Cash Flow | -543.61M |
Free Cash Flow Per Share (Quarterly) | -2.420 |
Free Cash Flow to Equity (Quarterly) | -203.94M |
Free Cash Flow to Firm (Quarterly) | -196.90M |
Free Cash Flow Yield | -16.57% |